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Abstract.
the extent
was to investigate 
the effects of hormonal replacement 
on
in postmenopausal women. In a hospital-based study
examinations of 81
women were evaluated retrospectively, before and af­
ter 1-2 years of treatment with oestrogens or a com­
bination of oestrogens and progestagens. Each indi­
vidual mammographie film was examined separately, 
and the glandular tissue was classified according to a
a screening-centre- 
based study two consecutive mammograms, with a 2- 
year interval, of 645 women, of whom 70 were using 
some kind of hormone therapy, were evaluated retro­
spectively. In the hospital-based study 31 % of pa­
tients treated with combination HRT showed an in-
crease m tibroglandular tissue 
8.7 % in the group treated with oestrogens alone.
was statistically significant {p = 
0.046). In the screening-based study 14.3 % of the wo­
men using hormonal therapy showed an increase, 
whereas in the non-users no increase was found 
(p = 1.24 x 10~l°). After beginning HRT many women 
(between 14 and 25 % in our experience) can be ex-
increase in
be aware of the aetiology of such changes, and can 
obtain information on HRT most conveniently by
Introduction
In The Netherlands hormonal replacement therapy 
(HRT) is widely prescribed for postmenopausal women 
for the treatment of perimenopausal symptoms [1, 2] 
and prevention of osteoporosis [3, 4]. Furthermore, 
HRT has been associated with a reduced risk of devel­
oping cardiovascular disease [5, 6]. Hysterectomized 
women are commonly treated with unopposed oestro­
gens, whereas the addition of a progestagen to the oes­
trogen is generally accepted in non-hysterectomized 
women to prevent the development of oestrogen-in­
duced endometrial hyperplasia and carcinoma [7].
There has been a breast cancer screening program in 
the city of Nijmegen since 1975. Recently, this program 
was expanded nationwide. A ll women between the 
ages of 50 and 70 years are being screened once every 
2 years. The women being screened are close to or al­
ready in the postmenopausal stage. Normally, the fibro- 
glandular breast tissue decreases, or at least remains sta­
ble, in this age group [8-12]. However, occasionally an 
increase in glandular tissue was noticed at mammogra­
phy. A ll these cases concerned postmenopausal women 
undergoing HRT. This study was therefore undertaken 
to investigate the frequency of parenchymal breast 
changes in postmenopausal women receiving HRT.
Subjects and methods
This study comprised two separate retrospective investi 
gations: a hospital-based study and a screening-centre 
based study of the changes in parenchymal breast chan 
ges during HRT.
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Hospital-based study
Hormonal replacement therapy. In this study mammo­
graphie examinations of 81 healthy postmenopausal wo­
men (mean age ± SD: 54.0 + 3.3 years) receiving HRT in
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Table 1. Hospital-based study: distribution of hormone replace­
ment therapy (HRT)
Group Ia 
(n = 21)
Group IIb 
(n = 30)
Group IIIe 
(n = 30)
Total group 
(n = 81)
Oestrogen and 
progestagen 21 24 13 58
Oestrogen alone 0 6 17 23
a 17/3-oestradiol combined with dydrogesterone 
b Conjugated oestrogens, either alone or combined with medroxy­
progesterone
c Conjugated oestrogens, either alone or combined with medroges- 
tone
one of three prospective clinical trials in the gynaeco­
logical outpatient department of our university hospital 
were reviewed. The participating subjects had given 
their written informed consent after the nature of the 
study had been fully explained. A  total of 21 non-hy- 
sterectomized women (mean age ± SD: 54*5 ± 3,3 years) 
received micronized 176-oestradiol (2 mg daily; Zume- 
non, Solvay-Duphar BV, Weesp, Tire Netherlands) in 
combination with dydrogesterone ('10 mg daily; 
Duphaston, Solvay-Duphar BV, Weesp, The Nether­
lands) during the first 14 days of each 28-day treatment 
cycle for a period of 2 years [13]. A  total of 30 non-hy- 
sterectomized women (mean age ± SD: 53.6 + 3.7 years) 
received conjugated oestrogens (0.625 mg daily; Pre- 
marin, Wyeth-Ayerst Laboratories, Philadelphia, Pa.) 
either alone or in combination with medroxyprogester­
one acetate, 2.5 or 5.0 mg daily continuously, or 5.0 or
10.0 mg daily for the last 14 days of each 28-day treat­
ment cycle for a period of 1 year. A  total of 30 hysterec­
tomized women (mean age±SD: 53.9 ± 3.0 years) re­
ceived conjugated oestrogens (0.625 mg daily; Pre- 
marin, Wyeth-Ayerst Laboratories, Philadelphia, Pa.) 
either alone or in combination with medrogestone 
(5 mg daily; Colpro, Wyeth-Ayerst Laboratories, Hoof- 
ddorp, The Netherlands), during the last 12 days of 
each 28-day treatment cycle for a period of 1 year [14]. 
A  combination of oestrogens and progestagens had 
been prescribed for 58 women (mean age±SD: 
53.4 ± 2.7 years), and the remaining 23 women (mean 
age±SD: 54.2 ± 3.5 years) had been treated with oes­
trogens alone (Table 1).
Mammography. Mammography was performed before 
starting and after either a 1- or 2-year period of HRT as 
stated above. The patients were otherwise healthy and 
had no prior breast cancer or major breast surgery. 
Each individual mammographic film, left and right, be­
fore and after HRT,was examined randomly and sepa­
rately by three radiologists. The 324 mammograms 
were classified according to a modified Wolfe classifica­
tion into one of four groups [15]. The Wolfe classifica­
tion of breast parenchymal patterns was established in 
1976. Since that time it has been challenged widely [16, 
17], and alternative classifications have been intro­
duced. In order to describe the breast pattern in our 
populations we modified the Wolfe classification to be
re-classified by density alone. This modification did not 
alter the four original groups outlined by Wolfe, because 
we used the same percentage boundaries (Fig. 1). An in­
crease in breast density was considered if at least two 
readings of every mammogram showed a change into a 
higher group according to the modified Wolfe classifica­
tion. This method provides more objective proof of a 
real difference, but may serve to underestimate the ac­
tual difference. With a direct comparison of the two 
mammograms marginal differences of parenchymal 
density, which would fail to cause a jump from one clas­
sification category to the next, would also be recorded.
Screening-centre-based study
In an investigation separate from the above-mentioned 
hospital-based study, 710 consecutive mammographic 
examinations from our breast cancer screening program 
were evaluated. The current examination was compared 
with the previous screening mammography made 
2 years earlier, to evaluate changes in fibroglandular 
densities, correlated with the use of hormonal therapy 
by these women. A  total of 65 women came in for their 
first screening mammography and were therefore ex­
cluded from the study. There were 70 women using 
some kind of hormonal therapy, either contraceptive or 
HRT. No data concerning the individual drugs used, 
their dosage or the duration of therapy was collected. 
In total, 645 women between the ages of 50 and 70 years 
were evaluated for changes in the fibroglandular breast 
tissue according to the modified Wolfe classification.
Radiographic technique
All mammograms were obtained by using a high-resolu- 
tion screen-film combination (Kodak Min-RH East- 
man-Kodak, Rochester, N. Y.) and mammography was 
performed on dedicated mammographic equipment [pri­
marily General Electric CGR Senographe 600T (Gener­
al Electric Medical Systems Nederland BV, ’s Hertogen- 
bosch, The Netherlands), and to a lesser extent, Sore- 
dex/Enraf Mamex dcS (Soredex, Orion Corporation, 
Nilsiankatu, Finland) and Mammomat 3 (Siemens, Er­
langen, Germany)]. Mammography consisted of a stan­
dard mediolateral oblique (M LO) view and a craniocau- 
dal (CC) view in the hospital-based study. In our breast 
cancer screening centre the initial screening comprised 
an MLO as well as a CC view, whereas on subsequent vis­
its the CC view was only added on indication. These indi­
cations comprised palpable lesions, mammographically 
dense breasts, lesions described on the previous mammo­
graphy and/or changes on the current MLO mammo­
gram as compared with the previous examination.
Statistical analysis
For all differences tested on statistical significance we 
used the Fisher exact test.
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Fig-1 a-d. Classification of breast parenchymal patterns, a Paren­
chyma composed primarily of fat with small areas of increased 
density; b parenchyma mainly fat with densities in the anterior 
portion of the breast up to a quarter of the breast volume; c paren­
chyma consisting mainly of densities occupying more than a quar­
ter of the breast volume; d parenchyma with large areas of in­
creased density which obscures the underlying architecture
Results
Hospital-based study
A  total of 20 of 81 women (24.7 %) showed an increase 
in fibroglandular tissue at mammography (Figs. 2, 3). In 
the group of women receiving a combination of oestro- 
gens and progestagens, 18 of 58 (31%) showed an in­
crease in glandular density Of the remaining 23 pa­
tients, treated with oestrogens alone, only 2 women
(8.7%) had an increase in glandular breast tissue (Ta­
ble 2). The Fisher exact test showed a significant differ­
ence (p = 0.046) between the percentages of women 
with increased glandular breast density in the oestrogen 
replacement therapy group and the combined oestro­
gen/progestagen replacement therapy group. In all 20 
cases the increase in fibroglandular tissue was bilateral; 
no unilateral increase was found in this study.
O f all 81 women in this study, only 4 showed either a 
unilateral or bilateral decrease in fibroglandular tissue 
within the intervening interval between the two mam- 
mographic examinations; in all other cases the breast 
densities remained unchanged. In some cases we also no­
ticed an increase in breast volume during HRT. These 
findings were incidental; no significant trend could be es­
tablished. Within the group of 20 women showing an in­
crease in fibroglandular breast tissue, no fibroadenomas 
or cysts could be detected mammographically without 
the use of ultrasonography, either before or after HRT.
Table 2. Hospital-based study: effects of HRT
Increase in breast density No change in breast density Decrease in breast density Total group
(n = 20)
11 (n = 4) (n = 81)
Oestrogen and progestagen 18(31%) 37 3 58
Oestrogen alone 2 (87 %) 20 l a 23
a Decrease in breast density in one breast
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Fig. 2. a Baseline mammography of a 58-year-old woman, classi­
fied into group 2; b mammograms obtained after 2 years of hor­
mone replacement therapy (HRT) show a marked increase in fi- 
broglandular tissue (from groups 2 to 3)
Fig. 3. a Baseline mammography of a 50-year-old woman shows 
heterogeneous breast parenchyma, classified into group 2; b mam­
mograms obtained after 13 months of combined oestrogen/proge­
stagen replacement therapy show diffuse increase in fibroglandu- 
lar density (from groups 2 to 3)
showed any increase at all. The breast tissue decreased 
or remained stable in this group (Table 3). The Fisher 
exact test showed a highly significant difference (p = 
1.24 x 10"10) between the group of women using hor­
monal therapy and the group without hormonal therapy. 
The majority of the women started with hormonal ther­
apy during the interval between the two mammograms 
evaluated in this investigation, including all 10 women 
with an increase in fibroglandular tissue.
Table 3. Screening center-based study: effects of HRT
Increase in 
breast density 
(n = 10)
No increase in 
breast density
(n = 635)
lo tal 
group
(n = 645)
Hormonal
therapy 10 (14.3%) 60 70
No hormonal
therapy 0 575 575
Screening-centre-based study
The breast cancer screening centre-based investigation 
revealed 10 of 70 women (14.3 %) undergoing hormonal 
therapy (either contraceptive or postmenopausal), 
showing an increase in glandular tissue, whereas none 
of the remaining 575 women without hormonal therapy
Discussion
In this study we found a considerable percentage of wo­
men (24.7 %) using HRT who demonstrated an increase 
in fibroglandular breast density as demonstrated by re­
peat mammography. A  statistically significant differ­
ence between the frequency of mammographic changes 
in women treated with combined oestrogens and 
progestagens (31 %) and women treated with oestro­
gens alone (8.7 %) was found. Although statistically sig­
nificant, the numbers in the latter group are small and 
therefore warrant extended research.
In our screening-centre-based study 14.3 % (10 of 70) 
showed an increase in breast density, compared with 
24.7 % (20 of 81) in the hospital-based group. Although 
the two studies are not fully comparable, the difference 
in percentages may be clarified by a few points:
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Fig. 4. a Baseline mammography of a 57-year-old woman, classi­
fied into group 2; b mammograms obtained after 13 months of 
oestrogen/progestagen replacement therapy show a marked in­
crease in glandular density from groups 2 to 3; c Sixteen months 
after cessation of IiRT, there is a decrease in breast densities back 
to near-baseline levels; d the same patient 11 months after enter­
ing another HRT trial, showing a renewed increase in fibroglandu­
lar breast tissue
1. Hormonal therapy was not closely monitored in the 
screening centre-based group, as was the case in the 
highly motivated hospital-based group of women.
2. The information about hormonal therapy in the 
screening-based group was based solely on the recollec­
tions of the individual women.
3. Within the hormonal therapy group in the screening- 
based study, contraceptive medication was also in­
cluded.
In the recent literature there is a retrospective study by 
Berkowitz et al. [18] comprising a group of 30 women 
(aged 39-66 years, mean age 55.7 years) receiving 
HRT, of whom 16 used combined oestrogens/progestag- 
ens (mean treatment 17.8 months, range 3-30 months), 
and 14 received oestrogens alone (mean treatment
27.2 months, range 1-72 months). Five women (17%), 
all treated with combined hormonal therapy, showed 
an increase in fibroglandular tissue in response to HRT.
This effect showed a statistically significant difference 
(p = 0.045) from the oestrogen-alone group. In another 
retrospective study by Stomper et al. [19] 50 postmeno­
pausal women (median age 52 years, range 40-69 years) 
were treated with either oestrogens alone (n = 12) or a 
combination of oestrogens and progestagens (n ~ 38), 
for a median period of 18 months (range 6-39 months). 
Two oestrogen-alone users (17%) and 10 oestrogen/ 
progestagen users (26 %) showed increased breast den­
sities, but this difference was not statistically significant.
Parts of both above-mentioned studies show similari­
ties with our investigations, e.g. the evaluation of both 
an oestrogen therapy group and a combination oestro­
gen/progestagen therapy group [18,19]; the median age 
and the median follow-up period of the populations in­
vestigated [18,19]; the percentage of women with an in­
crease in fibroglandular tissue after HRT [19]; and the 
statistically significant difference between the oestrogen 
group and the oestrogen/progestagen group [18], How­
ever, there are some differences also. In our hospital- 
based study we evaluated 81 women, which is approxi­
mately two times more than the other two studies. Prob­
ably therefore we found a statistically significant differ­
ence between the frequency of mammographic changes 
in women treated with combined oestrogens and 
progestagens and women treated with oestrogens alone. 
Another difference is that in our study each individual 
mammographic film, left and right, before and after
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HRT, was examined randomly and separately and classi­
fied according to a modified Wolfe classification into 
one of four groups by three radiologists. In  both above- 
mentioned studies [18, 19] this systematically blinded 
procedure was not used; instead, all mammographic ex­
aminations of the individual women before and after 
HRT were analysed simultaneously.
The statistically significant difference between the 
women being treated with oestrogen alone and those 
treated with a combination of oestrogen and proge­
stagen is consistent with other published investigations 
[18-20]. It is suggested that in addition to the effects of 
oestrogens on breast tissue, progestagens have an am­
biguous influence on the mammary duct epithelium. Be­
sides a known antagonistic response, progestagens act in 
synergism with oestrogens especially on the distal por­
tion of the ducts [21]. Furthermore, Key and Pike [22] 
described that the mitotic rate of breast cells is higher 
during the luteal phase of the menstrual cycle than dur­
ing the follicular phase, which could be interpreted to 
suggest a progestagen influence. These two observations 
may contribute to the explanation of the significant dif­
ference between the oestrogen-alone group and the 
combined oestrogen/progestagen group found in our 
study.
In those women investigated some time after cessa­
tion of HRT we found a decrease in mammographic tis­
sue density almost to the levels prior to HRT. This is in 
accordance with other studies [18-20]. In a couple of 
our cases there was a renewed prescription for replace­
ment therapy, which resulted in an immediate increase 
in glandular density (Fig. 4). This again strongly indi­
cates a causal relationship between an increase in fibro- 
glandular breast tissue and HRT.
Numerous epidemiological studies on the risk of 
breast cancer for postmenopausal women after treat­
ment with HRT, either oestrogens alone or a combina­
tion of oestrogens and progestagens, have been con­
ducted [22-28]. The results of these studies are contra­
dictory. There are studies showing no increased risk af­
ter HRT [23, 24], whereas other investigations suggest 
a slightly increased risk of breast cancer [22, 25, 26]. 
There is a growing consensus that there is a tendency 
for the risk to increase with increasing duration of treat­
ment. Bergkvist et al. [26] found a relative risk of 1.7 in 
women with more than 9 years of HRT use. Hypotheti­
cally, the possibility exists that the relatively increased 
risk of breast cancer after prolonged use of HRT will af­
fect primarily those women showing increased fibro- 
glandular breast tissue at mammography after HRT. 
This of course can only be verified in an additional ex­
tensive and carefully set up investigation with a long­
term follow-up.
After beginning HRT, many women (between 14 and 
25 % in our experience) can be expected to undergo a 
mammographically detectable increase in fibroglandu- 
lar tissue. This contradicts the more common situation 
in which glandular density in non-treated women de­
creases or remains stable after menopause. Radiologists 
should be aware of the aetiology of such changes, which 
may hamper the detection of malignant lesions and can
obtain information on HRT most conveniently by hav­
ing the technologist routinely question each patient. 
Special attention should be given to these mammo­
graphic examinations for signs of incidental malignancy 
such as solid masses, architectural distortion, microcalci­
fications and/or skin changes. These women should be 
followed carefully, as the incidence of breast cancer in­
creases with age. Early and small carcinomas may not 
be detected as early as would be the case in women 
without HRT. Therefore, a more frequent (yearly) 
screening of these women should be considered in each 
case [29].
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